Home / Technology & Devices (page 10)

Technology & Devices

Bristol-Myers Squibb and Flatiron Health Expand Collaboration to Accelerate Cancer Research and Development Efforts

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their relationship today by announcing a three-year collaboration agreement. Bristol-Myers Squibb will use Flatiron’s real-world data to …

Read More »

Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo Fisher Scientific

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it has entered into an agreement with Thermo Fisher Scientific to leverage the Oncomine™ Dx Target Test as a companion diagnostic for …

Read More »

Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily’s Immunoscape platform to identify and better understand the immunological basis of three common and serious inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease …

Read More »

Fujirebio and Janssen Partner to Develop An Assay to Identify Patients that may Benefit from Janssen’s Investigational Alzheimer’s Disease Drug

MALVERN, Pa.–(BUSINESS WIRE)–Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the Company”) announced today that it has entered into an agreement with US-based Janssen Pharmaceuticals, Inc. (hereinafter “Janssen”) to develop and commercialize an AMYLOID β 42/40 RATIO …

Read More »

Personal Genome Diagnostics’ TMB Analysis Shows Promising Checkpoint Inhibitor Efficacy in Early-Stage Lung Cancer Study

BALTIMORE, April 19, 2018 /PRNewswire/ — Personal Genome Diagnostics Inc. (PGDx) today reported that its whole exome analysis platform contributed to an important new study published in the New England Journal of Medicine (NEJM) showing promising efficacy for a leading checkpoint inhibitor in early stage lung cancer.1 The study also …

Read More »

Bristol-Myers Squibb and Illumina Partner for Companion Diagnostics for Oncology Immunotherapies

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio. The companies plan to develop a diagnostic version of the Illumina …

Read More »

FDA Finalizes Guidances to Accelerate the Development of Reliable, Beneficial Next Generation Sequencing-Based Tests

The U.S. Food and Drug Administration today finalized two guidances to drive the efficient development of a novel technology that scans a person’s DNA to diagnose genetic diseases, which are usually hereditary, and guide medical treatments. The guidances provide recommendations for designing, developing, and validating tests that use the technology, …

Read More »

FDA Permits Marketing of Artificial Intelligence-Based Device to Detect Certain Diabetes-Related Eye Problems

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes. Diabetic retinopathy occurs when high levels of blood sugar lead to damage in the …

Read More »

Foundation Medicine and its Collaborators Present New Findings Supporting Comprehensive Genomic Profiling for Targeted Treatment

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced the presentation of new findings at the American Association for Cancer Research (AACR) Annual Meeting. The data supports the use of both tissue- and blood-based comprehensive genomic profiling (CGP) to advance personalized cancer care and inform the use of targeted and immunotherapy treatment …

Read More »

Illumina and Loxo Oncology Partner for Development of Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

SAN DIEGO & STAMFORD, Conn.–(BUSINESS WIRE)–Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication. The co-development partnership will …

Read More »